Hoth Therapeutics Inc
Company Profile
Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USAT: +1 646 756-2997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,686.30 | 8.30 | -0.10% |
| CAC 40 | 7,922.38 | 58.69 | -0.74% |
| DAX 40 | 23,010.29 | 268.56 | -1.15% |
| Dow JONES (US) | 45,752.26 | 386.51 | -0.84% |
| FTSE 100 | 9,451.18 | 76.47 | -0.80% |
| HKSE | 25,220.02 | 615.55 | -2.38% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,538.76 | 103.40 | -1.56% |
| S&P/ASX 200 | 8,416.50 | 0.00 | 0.00% |
| SSE Composite Index | 3,834.89 | 96.16 | -2.45% |